-Company Joins Supplier Base Offering Broad Array of Healthcare Products to
Patients with Immune Deficiency and Bleeding Disorders
OTTAWA, April 3, 2008 /PRNewswire/ -- CSL Behring Canada, Inc. today announced that Canadian Blood Services, and Hema-Quebec, have each awarded the company contracts to supply Helixate(R) FS (Antihemophilic Factor [Recombinant]), Humate(R) P (Antihemophilic factor / von Willebrand Factor Complex [Human], Dried, Pasteurized), Privigen (Immune Globulin Intravenous [Human]), Vivaglobin(R) (Immune Globulin Subcutaneous [Human]) and other plasma-derived products. These products are used for the treatment of conditions such as hemophilia, von Willebrand Disease, primary immunodeficiency as well as other serious conditions.
The contracts call for CSL Behring to supply the above mentioned life-saving therapies over a period of at least five years, and to provide toll manufacturing services to Canadian Blood Services for the fractionation of Canadian plasma. In addition, with this agreement, CSL Behring will become the main supplier of bleeding disorder treatments in the province of Quebec.
CSL Behring currently maintains a portfolio of 23 different products, which it develops, manufactures, and distributes to the global healthcare community. The company also offers comprehensive consumer support, research and education support, disease awareness campaigns and other initiatives to ensure that patients receive proper diagnoses and treatment interventions.
"We at CSL Behring in Canada are quite pleased with the awards," said
Dr. Heinz Neuhaus, General Manager of CSL Behring Canada. "Our company has
made significant investments in becoming a reliable partner for both
Canadian Blood Services and Hema-Quebec so that we can expand our product
offering to Canadian patients in need. It is gratifying to be recognized
with a supply agreement that allows us to strengthen even further our
commitment to saving and i
|SOURCE CSL Behring|
Copyright©2008 PR Newswire.
All rights reserved